Artificial intelligence continues to reshape biotech discovery and investment landscapes. Insilico Medicine unveiled its LEGION workflow to comprehensively explore drug-like chemical space while deterring competitor patenting. AstraZeneca inked a $555 million partnership with AI-driven firm Algen Biotechnologies to harness its genome-editing and single-cell platforms for novel immunology targets. Meanwhile, bicoastal TCG Crossover closed a $1.3 billion fund, betting on attractive biotech valuations amid industry headwinds.